TA176 Colorectal cancer (first line) - cetuximab and TA240 Colorectal cancer (metastatic) - panitumumab (terminated appraisal): review decision - January 2014
Review of NICE Technology Appraisal Guidance No.176; Cetuximab for the first-line treatment of metastatic colorectal cancer, and No.240; Panitumumab for the first-line treatment of metastatic colorectal cancer
The Institute was proposing that TA176 should be updated, along with a related technology appraisal (TA240).
During consultation, the majority of comments received by the Institute agreed with the proposal put forward. After consideration of all of the comments (attached as appendix A), the Institute’s Guidance Executive has decided to proceed with the proposal.
Therefore an update of TA176 and TA240 will be scheduled into technology appraisals work programme as a Multiple Technology Appraisal (MTA).
This page was last updated: 23 January 2014